Radiotherapy for renal-cell carcinoma - 01/04/14
, Vincent Khoo, MD c, Bernard Escudier, MD d, Steven Joniau, PhD f, Alberto Bossi, MD e, Piet Ost, MD a, Alberto Briganti, MD g, Valérie Fonteyne, MD a, Marco Van Vulpen, MD h, Nicolaas Lumen, PhD b, Martin Spahn, MD i, Marc Mareel, ProfMD aSummary |
Renal-cell carcinoma is considered to be a radioresistant tumour, but this notion might be wrong. If given in a few (even single) fractions, but at a high fraction dose, stereotactic body radiotherapy becomes increasingly important in the management of renal-cell carcinoma, both in primary settings and in treatment of oligometastatic disease. There is an established biological rationale for the radiosensitivity of renal-cell carcinoma to stereotactic body radiotherapy based on the ceramide pathway, which is activated only when a high dose per fraction is given. Apart from the direct effect of stereotactic body radiotherapy on renal-cell carcinoma, stereotactic body radiotherapy can also induce an abscopal effect. This effect, caused by immunological processes, might be enhanced when targeted drugs and stereotactic body radiotherapy are combined. Therefore, rigorous, prospective randomised trials involving a multidisciplinary scientific panel are needed urgently.
Le texte complet de cet article est disponible en PDF.Plan
Vol 15 - N° 4
P. e170-e177 - avril 2014 Retour au numéro
Article précédent
- Risk of CNS dissemination in extranodal lymphomas
- Andrés J M Ferreri
- Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review
- Aimilios Lallas, Athanassios Kyrgidis, Gerardo Ferrara, Harald Kittler, Zoe Apalla, Fabio Castagnetti, Caterina Longo, Elvira Moscarella, Simonetta Piana, Iris Zalaudek, Giuseppe Argenziano
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?